X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Abbott India with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs TEVA PHARMA (Israel) - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ABBOTT INDIA   TEVA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
TEVA PHARMA
Dec-13
ABBOTT INDIA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,1102,973-   
Low Rs3,9962,583-   
Sales per share (Unadj.) Rs1,552.21,706.3-  
Earnings per share (Unadj.) Rs188.8106.6-  
Cash flow per share (Unadj.) Rs196.4244.5-  
Dividends per share (Unadj.) Rs55.0093.31-  
Dividend yield (eoy) %1.13.4 32.4%  
Book value per share (Unadj.) Rs796.61,895.4-  
Shares outstanding (eoy) m21.25848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.6 200.0%   
Avg P/E ratio x26.826.1 102.7%  
P/CF ratio (eoy) x25.711.4 226.4%  
Price / Book Value ratio x6.31.5 432.8%  
Dividend payout %29.187.5 33.3%   
Avg Mkt Cap Rs m107,3762,355,719 4.6%   
No. of employees `0003.344.9 7.4%   
Total wages/salary Rs m3,9370-   
Avg. sales/employee Rs Th9,929.332,194.2 30.8%   
Avg. wages/employee Rs Th1,185.10-   
Avg. net profit/employee Rs Th1,207.72,011.1 60.1%   
INCOME DATA
Net Sales Rs m32,9851,446,966 2.3%  
Other income Rs m1,1700-   
Total revenues Rs m34,1551,446,966 2.4%   
Gross profit Rs m5,245396,252 1.3%  
Depreciation Rs m162116,960 0.1%   
Interest Rs m3828,421 0.1%   
Profit before tax Rs m6,215250,872 2.5%   
Minority Interest Rs m01,140 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-164,684 0.0%   
Tax Rs m2,203-3,063 -71.9%   
Profit after tax Rs m4,01290,391 4.4%  
Gross profit margin %15.927.4 58.1%  
Effective tax rate %35.4-1.2 -2,903.0%   
Net profit margin %12.26.2 194.7%  
BALANCE SHEET DATA
Current assets Rs m22,655977,276 2.3%   
Current liabilities Rs m6,681852,267 0.8%   
Net working cap to sales %48.48.6 560.5%  
Current ratio x3.41.1 295.7%  
Inventory Days Days6591 71.3%  
Debtors Days Days2996 30.4%  
Net fixed assets Rs m835472,611 0.2%   
Share capital Rs m2133,562 6.0%   
"Free" reserves Rs m16,7150-   
Net worth Rs m16,9281,607,305 1.1%   
Long term debt Rs m0739,866 0.0%   
Total assets Rs m24,1623,306,782 0.7%  
Interest coverage x163.79.8 1,665.7%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.40.4 312.0%   
Return on assets %16.83.6 466.6%  
Return on equity %23.75.6 421.5%  
Return on capital %36.94.9 749.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-3,4380-   
CASH FLOW
From Operations Rs m1,527230,572 0.7%  
From Investments Rs m-2,148-81,701 2.6%  
From Financial Activity Rs m-1,024-276,586 0.4%  
Net Cashflow Rs m-1,646-127,715 1.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 71.23 Rs / USD

Compare ABBOTT INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare ABBOTT INDIA With: NATCO PHARMA  GLENMARK PHARMA  FRESENIUS KABI ONCO.  JUBILANT LIFE SCIENCES  PLETHICO PHARMA  



Today's Market

Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.

Related Views On News

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 20, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS